The effect of Hydroxyethyl Starch (Voluven) On Hemorrhagic Shock Treatment.

Phase 3

• Conditions: Hemorrhagic Shock.; Failure of peripheral circulation NOS

• Registration Number: IRCT2014052114190N3
• Lead Sponsor: Vice Chancellor for Research and Technology Development-Ahwaz Jondishapur University of Medical Sci

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

The study included all patients with traumatic hemorrhagic shock who were referred to the Imam Khomeini hospital in Ahvaz, Iran. Exclusion criteria: Heart failure (reduced heart function with clinical symptoms: orthopnea, exertional dyspnea, MET <4 and EF <50%); Patient who received Blood before the study completed; Patient died before completing the study; Sensitivity to serum; Transfer to the operating room before the study completed; Hepatic insufficiency (decreased liver function with decreased albumin, increased PT, clinical and liver enzymes could be increased more than 5 times); Respiratory failure (lung function decline with increasing Pco2> 50 or drop in Po2 <60 or observed clinical signs of respiratory distress); Renal impairment: decreased renal function (GFR <60 mL/min/1.73 m2 for at least three months, or significant proteinuria); Sepsis: The presence of SIRS (Systemic Inflammatory Response Syndrome) with prove microbial etiology; Severe anemia (Hb <10); Patients who are considered for the diagnosis of non hemorrhagic shock; Patients with a history of sensitivity to the Solutions used in this study.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Base Excess. Timepoint: Before and after fluid therapy. Method of measurement: Measured by drawing a sample of arterial blood gas (ABG).

Secondary Outcome Measures

Name	Time	Method
Shock Index. Timepoint: after serum therapy. Method of measurement: If the shock index (heart rate / systolic blood pressure) is greater than one is considered positive.